ROIV Overview
Upcoming Projects (ROIV)
-
Evaluating the Phase 2a Results of Batoclimab for Graves' Disease and the Potential of IMVT-1402 by Roivant Sciences (ROIV)
Ticker: ROIV
Execute By: Nov 30, 2024
Executed Projects (ROIV)
-
A Second Look: Assessing Roivant's Phase 1b ATMOS Study Results of Mosliciguat in Pulmonary Hypertension and Its Potential for PH-ILD
Ticker: ROIV
Executed On: Oct 02, 2024 at 10:35 AM EDT -
Assessing Roivant's Phase 1b ATMOS Study Results of Mosliciguat in Pulmonary Hypertension and Its Potential for PH-ILD
Ticker: ROIV
Executed On: Sep 20, 2024 at 10:45 AM EDT -
A Second Look: Discussing the potential of Roivant's batoclimab for normalizing of T3 and T4 hormone levels in patients with Graves’ disease
Tickers: IMVT, ROIV
Executed On: Feb 21, 2024 at 01:15 PM EST -
A third Look: Discussing the potential of Roivant's batoclimab for normalizing of T3 and T4 hormone levels in patients with Graves’ disease
Tickers: IMVT, ROIV
Executed On: Jan 19, 2024 at 09:00 AM EST -
Discussing the potential of Roivant's batoclimab for normalizing of T3 and T4 hormone levels in patients with Graves’ disease
Tickers: ROIV, IMVT
Executed On: Jan 17, 2024 at 07:00 PM EST -
Getting a community dermatologist's perspective on plaque psoriasis non-steroid topical treatments including Roivant's VTAMA (tapinarof) and Arcutis' Zoryve (roflumilast)
Tickers: ROIV, ARQT, INCY
Executed On: Mar 07, 2023 at 01:00 PM EST -
Discussing therapies in development for plaque psoriasis with a focus on Dermavant VTAMA (tapinarof) cream and Arcutis' ZORYVE
Tickers: ROIV, ARQT
Executed On: Nov 01, 2022 at 01:00 PM EDT -
Discussion of VTAMA (tapinarof cream) with a KOL on plaque psoriasis
Ticker: ROIV
Executed On: Jun 21, 2022 at 03:00 PM EDT -
Discussing Arcutis' roflumilast vs. Dermavant's tapinatof for the treatment of psoriasis
Tickers: ARQT, ROIV
Executed On: Jun 09, 2022 at 01:00 PM EDT
Expired Projects (ROIV)
-
Transforming Treatment in Non-Infectious Uveitis: An In-Depth Look at Brepocitinib's NEPTUNE Study Success
Ticker: ROIV
Execute By: May 31, 2024 -
Discussing the UC landscape and how upcoming new therapies could affect that
Tickers: ROIV, MORF, TEVA
Execute By: Oct 27, 2023 -
Discussing Roivant subsidiary Dermavant Sciences’ recent Phase 3 data of tapinarof in plaque psoriasis ahead of the Q2 PDUFA
Ticker: ROIV
Execute By: Jun 30, 2022
Upcoming & Overdue Catalysts (ROIV)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ROIV)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
